ABBOTT INDIA LIMITED

Diamyd® treatment shows significant C-peptide preservation improvements across trials, supporting potential for precision medicine in Type 1 Diabetes, with a benign safety profile positioning it as a best-in-class immunotherapy.

Diamyd® immunotherapy shows significant C-peptide preservation in Type 1 Diabetes patients with HLA DR3-DQ2, supporting potential for precision medicine to delay disease progression.

Diamyd® immunotherapy shows significant C-peptide preservation in Type 1 Diabetes patients with HLA DR3-DQ2, supporting potential for precision medicine to delay disease progression.

VIVA Foundation announces results from VIVA24 conference, highlighting 8 late-breaking clinical trials on vascular medicine advancements, including limb salvage rates, durability of percutaneous transmural arterial bypass, retrievable scaffold therapy, sirolimus-coated balloon angioplasty, and diversity in clinical trials.

The global necrotizing fasciitis treatment market is expected to grow from USD 2.9 billion in 2024 to USD 4.5 billion by the forecast period's end, driven by personalized therapies, targeted antimicrobial treatments, and advanced imaging technologies. Key players are innovating with novel antibiotics, biologics, and less invasive surgical methods, while strategic collaborations accelerate breakthroughs. Recent developments include GSK's acquisition of Elsie Biotechnologies and Merck's partnership with Mycenax Biotech.

VIVA symposium highlights 9 late-breaking clinical trials, including LIFE-BTK's 2-year results showing Esprit BTK Drug-Eluting Resorbable Scaffold's superior efficacy over PTA in treating CLTI, and the Shockwave Javelin Peripheral IVL catheter's success in reducing target lesion stenosis without perforations or embolization. Other trials demonstrated the safety and effectiveness of IVL, laser-based IVL, and directional atherectomy with drug-coated balloons in treating calcified lesions, and the efficacy of transcarotid artery revascularization and mechanical thrombectomy for DVT and PE.

Pharma companies like Merck and Moderna spend significantly more on R&D than medtech firms, but higher spending doesn’t always correlate with more innovation output. Medtronic, with 8.45% R&D intensity, generated 443 patents and 305 publications in 2023, while Moderna, spending 70.75% of revenue on R&D, produced only 27 patents and 245 publications. Medtech firms consistently show higher patent output per R&D dollar invested.

FDA approves Abbott's FreeStyle Libre 2 and 3 CGMs for use during X-rays, CT scans, and MRIs, allowing patients to keep sensors on and avoid lost data.